Jan Holgersson, MD, PhD

"We are paving the way for the development of mucin-based biopharmaceuticals targeting the vaccine and anti-microbials markets."

"There are no roadmaps that we can follow to unlock the potential of mucin-based vaccines. We truly are making breakthroughs that will benefit both pharmaceutical and biotechnology companies, as well as protecting the health of people worldwide."

MD and PhD in Carbohydrate Biochemistry from the University of Gothenburg
Post-doctoral training at Harvard Medical School in Boston
Professor in Transplantation Immunology at Sahlgrenska Academy and
Clinical responsibilities as a transplant immunologist at Sahlgrenska University Hospital, Gothenburg

Back to researchers